Messenger RNA vaccines and neutralizing anti-severe acute respiratory syndrome coronavirus 2 antibodies in patients with immunodeficiency.
作者信息
Mungmunpuntipantip Rujittika, Wiwanitkit Viroj
机构信息
Private Academic Consultant Center, Bangkok, Thailand.
Department of Community Medicine, Dr DY Patil University, Pune, India.
出版信息
Ann Allergy Asthma Immunol. 2021 Dec;127(6):703. doi: 10.1016/j.anai.2021.09.007.
Abstract
摘要
相似文献
1
Messenger RNA vaccines and neutralizing anti-severe acute respiratory syndrome coronavirus 2 antibodies in patients with immunodeficiency.免疫缺陷患者中的信使核糖核酸疫苗及中和抗严重急性呼吸综合征冠状病毒2抗体
Ann Allergy Asthma Immunol. 2021 Dec;127(6):703. doi: 10.1016/j.anai.2021.09.007.
2
Strong Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Neutralizing Antibody Response of Previously Infected Healthcare Workers Given 1 Dose of mRNA Vaccine.曾感染过新冠病毒的医护人员接种一剂mRNA疫苗后的强效严重急性呼吸综合征冠状病毒2（SARS-CoV-2）中和抗体反应
Clin Infect Dis. 2022 Mar 1;74(4):746. doi: 10.1093/cid/ciab573.
3
Immunogenicity and safety of SARS-CoV-2 vaccines in clinical trials.临床试验中 SARS-CoV-2 疫苗的免疫原性和安全性。
Front Biosci (Landmark Ed). 2021 Nov 30;26(11):1286-1304. doi: 10.52586/5024.
4
The British variant of the new coronavirus-19 (Sars-Cov-2) should not create a vaccine problem.新冠病毒-19（Sars-Cov-2）的英国变体不应造成疫苗问题。
J Biol Regul Homeost Agents. 2021 Jan-Feb;35(1):1-4. doi: 10.23812/21-3-E.
5
Immediate Reactions After the First Dose of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Messenger RNA Vaccines Do Not Preclude Second-Dose Administration.在接种第一剂严重急性呼吸综合征冠状病毒 2（SARS-CoV-2）信使 RNA 疫苗后立即出现的反应并不会妨碍接种第二剂。
Clin Infect Dis. 2021 Dec 6;73(11):2108-2111. doi: 10.1093/cid/ciab448.
6
Serum Neutralizing Activity of mRNA-1273 against SARS-CoV-2 Variants.mRNA-1273 对 SARS-CoV-2 变异株的血清中和活性。
J Virol. 2021 Nov 9;95(23):e0131321. doi: 10.1128/JVI.01313-21. Epub 2021 Sep 22.
7
[SARS-CoV-2 vaccines].[严重急性呼吸综合征冠状病毒2型疫苗]
Ugeskr Laeger. 2021 Mar 8;183(10).
8
9
mRNA vaccine effectiveness against asymptomatic severe acute respiratory coronavirus virus 2 (SARS-CoV-2) infection over seven months.七个月内mRNA疫苗对无症状严重急性呼吸综合征冠状病毒2（SARS-CoV-2）感染的有效性
Infect Control Hosp Epidemiol. 2022 Mar;43(3):393-395. doi: 10.1017/ice.2021.399. Epub 2021 Sep 6.
10
New vaccine production platforms used in developing SARS-CoV-2 vaccine candidates.用于开发 SARS-CoV-2 候选疫苗的新型疫苗生产平台。
Vaccine. 2021 Jan 8;39(2):197-201. doi: 10.1016/j.vaccine.2020.11.054. Epub 2020 Nov 24.
本文引用的文献
1
Detection of neutralizing anti-severe acute respiratory syndrome coronavirus 2 antibodies in patients with common variable immunodeficiency after immunization with messenger RNA vaccines.在接受信使核糖核酸疫苗免疫的常见可变免疫缺陷患者中检测中和抗严重急性呼吸综合征冠状病毒2抗体
Ann Allergy Asthma Immunol. 2021 Oct;127(4):499-501. doi: 10.1016/j.anai.2021.07.026. Epub 2021 Aug 2.
2
Do COVID-19 RNA-based vaccines put at risk of immune-mediated diseases? In reply to "potential antigenic cross-reactivity between SARS-CoV-2 and human tissue with a possible link to an increase in autoimmune diseases".基于新冠病毒RNA的疫苗会引发免疫介导疾病的风险吗？回应“严重急性呼吸综合征冠状病毒2与人体组织之间潜在的抗原交叉反应可能与自身免疫性疾病增加有关”。
Clin Immunol. 2021 Mar;224:108665. doi: 10.1016/j.clim.2021.108665. Epub 2021 Jan 8.
3
Autoimmunity in common variable immunodeficiency.普通变异性免疫缺陷中的自身免疫。
Ann Allergy Asthma Immunol. 2019 Nov;123(5):454-460. doi: 10.1016/j.anai.2019.07.014. Epub 2019 Jul 23.
4
Common variable immune deficiency and autoimmunity.普通可变免疫缺陷与自身免疫
Autoimmun Rev. 2006 Aug;5(7):465-70. doi: 10.1016/j.autrev.2006.03.010. Epub 2006 Apr 24.
Zotero 插件